Welcome to our dedicated page for Theratechnologies Common news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies Common stock.
Theratechnologies Inc. (symbol: THTX) is a biopharmaceutical company that markets prescription products across the United States, Europe, and Canada. Founded in 1993 and headquartered in Montreal, Canada, the company is dedicated to addressing the unmet medical needs of patients living with HIV and other serious health conditions.
Core Products:
- EGRIFTA and EGRIFTA SV: These products help reduce excess abdominal fat in HIV-infected patients with lipodystrophy, improving their quality of life.
- Trogarzo: A vital injection treatment for multidrug-resistant HIV-1 infected patients, offering hope to those who have limited treatment options.
Pipeline Products:
- F8 Formulation: A promising treatment for HIV-associated lipodystrophy, currently in development.
- TH-1902: A potential breakthrough in the treatment of triple-negative breast cancer.
- TH-1904: Targeting ovarian cancer, another pipeline product with significant potential.
Theratechnologies generates significant revenue from its relationship with RxCrossroads, a major customer based in the United States. The company's strategic partnerships and innovative products showcase its commitment to improving patient outcomes in serious medical conditions. With a dedicated focus on research and development, Theratechnologies continues to make strides in the biopharmaceutical industry.
Theratechnologies Inc. (THTX) unveiled promising preclinical data for its investigational peptide drug conjugate, sudocetaxel zendusortide (TH1902), during the 2023 AACR meeting. The data suggest that this candidate can enhance immune cell infiltration in 'cold' tumors and boost efficacy alongside PD-L1 checkpoint inhibitors. In melanoma models, the combination of sudocetaxel zendusortide and PD-L1 therapy showed improved tumor inhibition and survival rates. In breast cancer models, it achieved complete tumor regression, outperforming docetaxel and Herceptin combinations. The expression of SORT1, targeted by TH1902, was noted in 60-75% of TNBC and HER2+ cases, supporting its development. The FDA has granted fast track designation for TH1902, although a Phase 1 trial is currently on hold pending protocol amendments.
FAQ
What is the current stock price of Theratechnologies Common (THTX)?
What is the market cap of Theratechnologies Common (THTX)?
What does Theratechnologies Inc. specialize in?
Where are Theratechnologies' products marketed?
What are the main products offered by Theratechnologies?
What are Theratechnologies' pipeline products?
When was Theratechnologies Inc. founded?
Where is Theratechnologies Inc. headquartered?
Who is a major customer of Theratechnologies?
What is the significance of Trogarzo?
How does EGRIFTA benefit HIV patients?
What is Theratechnologies' approach to innovation?
